Fig. 3: Immunogenicity of H39–68 and H68-39 chimeric VLPs. | npj Vaccines

Fig. 3: Immunogenicity of H39–68 and H68-39 chimeric VLPs.

From: Characterization of an Escherichia coli-derived triple-type chimeric vaccine against human papillomavirus types 39, 68 and 70

Fig. 3

a Schematic representation of the chimeric HPV39/68 L1 proteins based on WT HPV39 and HPV68 L1. b Immunogenicity of HPV39/68 chimeric VLPs in BALB/c mice delivered at three dosages. BALB/c mice (n = 5) were inoculated intraperitoneally with a high (5 μg/dose), middle (1 μg/dose), or low (0.2 μg/dose) dose of WT HPV39, HPV68 and HPV39/68 chimeric VLPs at weeks 0, 2, and 4. Neutralization antibody levels at week 8 after the first immunization were tested by neutralization assays. The dotted line indicates the limit of detection for the assay. All data were analyzed by one-way analysis of variance (ANOVA) and are presented as the mean ± standard deviation (SD); *P < 0.05, **P < 0.01; ***P < 0.001; ****P < 0.0001. The error bars reflect the SD and symbols represents individual mice.

Back to article page